Yao, Shuyang
Janku, Filip
Subbiah, Vivek http://orcid.org/0000-0002-6064-6837
Stewart, John
Patel, Sapna Pradyuman
Kaseb, Ahmed
Westin, Shannon Neville http://orcid.org/0000-0002-1922-0156
Naing, Aung http://orcid.org/0000-0002-4803-8513
Tsimberidou, Apostolia Maria
Hong, David
Piha-Paul, Sarina Anne
Shi, Nai
Johnston, Amanda
Bomalaski, John
Fu, Siqing http://orcid.org/0000-0002-1933-0419
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA016672, P30 CA016672)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 24 September 2020
Revised: 2 December 2020
Accepted: 10 December 2020
First Online: 5 March 2021
Ethical approval and consent to participate
: No formal ethics approval was applicable in our study. This clinical study was reviewed and approved by the Institutional Review Board (IRB) at the University of Texas MD Anderson Cancer Center. The study was performed according to the principles defined by the Declaration of Helsinki and Good Clinical Practice guidelines. All patients gave written informed consent prior to any study-related procedure.
: All data supporting the results in this manuscript are available at Polaris Pharmaceuticals, Inc.
: A.J. and J.B. are employees of Polaris Pharmaceuticals, Inc. The remaining authors declare no competing interests.
: The trial was funded by Polaris Pharmaceuticals, Inc. This research was also funded in part through the NIH/NCI Cancer Center Support Grant P30 CA016672. S.V.W. is supported by a NIH 1P50CA217685–01 SPORE in Ovarian Cancer and a GOG Foundation Scholar Investigator Award.